Producers of SmartTRAK, the only real-time, business intelligence system. We track company, product & competitive data for orthopedics, woundcare & neuro.
The numbers are hard to ignore: 74% of U.S.-based medical device startups fail to return capital to investors regardless of clinical merit or regulatory clearance. The #1 cause of startup failure isn't scientific or regulatory. It's no ...
https://t.co/9Pkx9wvDe2
Mapping the Future of Osteoarthritis - Incoming OARSI President Nancy Lane discusses the evolving landscape of OA treatment, "tissue crosstalk" and emerging breakthrough therapies in an interview with SmartTRAK at the 2026 OARSI World Co...
https://t.co/2n9JVYyQze
US Wound Care Market Poised for Change as Players Look to Shape the Future: SAWC Spring 2026 - SmartTRAK reports from SAWC Spring in Charlotte, NC, and finds a market rebuilding following a significant reimbursement shift ... #woundcare#SAWC2026
https://t.co/dynWWbioMB
Take a deeper dive into real-world data applications and actionable intelligence that drive growth, innovation and market differentiation in Ortho, Wound and Neuro Therapies at SmartTRAK In2Data 2026 ... #woundcare#orthopedics#neurotherapies
https://t.co/rC8Tv24FDt
How DME Suppliers are Driving the Growth of US Collagen Dressings – Part 2 - In this second part of a two-part series, SmartTRAK focuses on how DME suppliers are driving growth of the US Collagen Dressing Market. #orthobiologics#woundcare
https://t.co/Y77te8rhVh
Moving Beyond Collagen: Alafair's Innovative Approach to Frictionless Soft Tissue Healing - SmartTRAK interviewed Alafair’s leadership to discuss how their proprietary alginate technology is disrupting a market long dominated by collagen-based scaffold...
https://t.co/Qx3ODQYDOj
The Future of Pain Management and Osteoarthritis Therapy Pacira BioSciences’ CEO Frank Lee discusses advances in orthopedic pain mgmt, real-world evidence from the IGOR registry and PCRX-201, a gene therapy in development targeting osteoart...
https://t.co/0pFhUjmqMW
Integrating Ranfac’s Manufacturing Legacy With Cervos’ Biologic Distribution - Ranfac CEO Harlan Adler discusses the company's strategic pivot from contract manufacturing to owning clinical technologies ... #orthobiologics#regenmed#Ranfrac
https://t.co/dC1SwPrUlP
Could Enhanced Collagen Offer a New Solution in Skin Substitutes? - SmartTRAK interviews two HYFACOL Limited executives about their collagen manufacturing platform, HyFaCol ... #woundcare#HyFaCol
https://t.co/VlR1cwuaTg
Challenges and Opportunities in the Endovascular Treatment of Cerebral Venous Disorders - Ferdinand Hui, MD, discusses the endovascular treatment of cerebral venous disorders in this emerging field in an interview with SmartTRAK at 2026 SNIS ... #ne...
https://t.co/77WVBJhaZL
Soft Tissue Replacement: Trends to Watch in 2026 - SmartTRAK discusses the Soft Tissue Replacement Market landscape and what to expect in 2026 ... #softtissuereplacement#orthobiologics
https://t.co/SsHxvTMUrC
Matching Technology to Patient in the 2026 Cartilage Landscape - The 2026 cartilage replacement market is moving away from "one-size-fits-all" solutions toward a diversified, algorithm-driven approach tailored to specific biological profiles and patien...
https://t.co/zKuQTgBl1e
Neurovascular Intervention: Trends to Watch in 2026 - SmartTRAK highlights three neurointerventional trends, including a shift toward precision thrombectomy, a greater focus on expanded indications and building momentum in intrasaccular flow di...
https://t.co/huWgoYWgSg
An Interview with the Alliance of Wound Care Stakeholders - SmartTRAK interviews two leaders from the Alliance of Wound Care Stakeholders to discuss its aim to be the unified voice for the wound care community ... #woundcare
https://t.co/qRSJZR27rM